Batimastat
Title: Batimastat
CAS Registry Number: 130370-60-4
CAS Name: (2R,3S)-N4-Hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide
Additional Names: (2S,3R)-5-methyl-3-[[(aS)-a-(methylcarbamoyl)phenethyl]carbamoyl]-2-[(2-thienylthio)methyl]hexanohydroxamic acid; [4-(N-hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl)succinyl]-L-phenylalanine-N-methylamide
Manufacturers' Codes: BB-94
Molecular Formula: C23H31N3O4S2
Molecular Weight: 477.64
Percent Composition: C 57.84%, H 6.54%, N 8.80%, O 13.40%, S 13.43%
Literature References: Synthetic matrix metalloproteinase inhibitor. Prepn: C. Campion et al., WO 9005719; eidem, US 5240958 (1990, 1993 both to British Biotech.). Effect on transplanted human ovarian carcinoma: B. Davies et al., Cancer Res. 53, 2087 (1993). Inhibition of metastasis of transplanted human colorectal carcinoma: X. Wang et al., ibid. 54, 4726 (1994).
Properties: Fine white powder. mp 236-238°.
Melting point: mp 236-238°
Therap-Cat: Antineoplastic adjunct (antimetastatic agent).
Keywords: Antineoplastic Adjunct; Antimetastatic Agent; Matrix Metalloproteinase Inhibitor.

Others monographs:
LooplureChlordan(e)Water GasIndiplon
Carneginep-Bromomandelic AcidProtoverineHistrionicotoxin
TripamideInsulinaseSiccaninKahalalide F
Horse ChestnutTitanium SesquisulfateMeglumine Acetrizoateα-Phenylglycine
©2016 DrugLead US FDA&EMEA